EATONTOWN, N.J., April 30 /PRNewswire-FirstCall/ -- Osteotech, Inc.
(Nasdaq: OSTE), a leader in the emerging field of biologic solutions for
regenerative medicine, announced today that it has signed an exclusive
distribution agreement with BioHorizons, Inc., effective as of April 1,
2008, under which BioHorizons will market Osteotech's bone regeneration
products to the dental market in 29 countries in Europe, the Middle East,
Latin America and Asia. Osteotech and BioHorizons previously entered into
an agreement for BioHorizons to distribute Osteotech's products to the
United States dental market in 2000.
Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer,
commented, "Our domestic relationship with BioHorizons has been very
successful and we are pleased to be able to expand this relationship
overseas. We believe our bone regeneration products are the perfect
solution for the new bone grafting procedures being developed to replace
missing or extracted teeth with dental implants or as support for dentures,
crowns and bridges."
BioHorizons is a leading oral reconstructive device company at the
forefront of digital dentistry. The company has a broad product offering,
including surgical planning software, regenerative products, dental
implants, CAD/CAM and traditional dental restorations. BioHorizons has a
direct sales force in the U.S., Canada, Germany, Spain, United Kingdom,
Australia, Mexico, and Chile. Products are distributed in the rest of the
world via a network of independent distributors.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global
leader in providing OsteoBiologic solutions for regenerative medicine to
support surgeons and their patients in the repair of the musculoskeletal
system through the development of innovative therapy-driven products that
alleviate pain, promote biologic healing and restore function. For further
information regarding Osteotech or this press release, please go to
Osteotech's website at http://www.osteotech.com.
Certain statements made throughout this press release that are not
historical facts contain forward-looking statements (as such are defined in
the Private Securities Litigation Reform Act of 1995) regarding the
Company's future plans, objectives and expected performance. Any such
forward-looking statements are based on assumptions that the Company
believes are reasonable, but are subject to a wide range of risks and
uncertainties and, therefore, there can be no assurance that actual results
may not differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to
differ materially include, but are not limited to, the Company's ability to
develop and introduce new products, differences in anticipated and actual
product and service introduction dates, the ultimate success of those
products in the marketplace, the continued acceptance and growth of current
products and services, the impact of competitive products and services, the
availability of sufficient quantities of suitable donated tissue and the
success of cost control and margin improvement efforts. Certain of these
factors are detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission. All information in this
press release is as of April 30, 2008 and the Company does not intend to
update this information.
SOURCE Osteotech, Inc.
 back to top
Related links:
http://www.osteotech.com
http://www.prnewswire.com/comp/668050.html /
CONTACT:
Mark H. Burroughs of Osteotech, Inc.,
+1-732-542-2800
|
